Goodwin Procter advised Bicara Therapeutics on the offering, and Ropes & Gray advised the underwriters.Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced the pricing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
